DIMERIC RECOMBINANT IGA DIRECTED AGAINST CARCINO-EMBRYONIC ANTIGEN, A NOVEL TOOL FOR CARCINOMA LOCALIZATION

Abstract Carcinoembryonic antigen (CEA) has been shown to be one of the best markers for in vivo tumor targeting of radiolabeled antibodies, despite the fact that it is localized predominantly at the apical side of human colon carcinoma cells within the fairly closed pseudolumen structures formed by these tumors. Due to this particular histological localization, a large proportion of the CEA molecules may remain inaccessible to the intravenously injected radiolabeled anti-CEA antibodies of IgG isotype, which are widely used in the clinic. In order to improve targeting, we made a recombinant dimeric IgA, which should have the capacity to translocate from the basolateral to the apical side of the pseudolumen formed by colon carcinoma cells after binding to the poly Ig receptor (plgR). A genomic chimeric mouse-human IgA 2 construct was made using one of our most specific anti-CEA hybridomas, CE-25. The chimeric IgA (chlgA) was expressed in the Sp2/0 myeloma cell line. The secreted recombinant antibody was found to consist mostly of a dimeric form of IgA with a molecular weight of about 350 kDa. The dimeric chlgA was shown to translocate efficiently in vitro across a monolayer of epithelial cells expressing the plgR and to retain full CEA binding activity.